TLC Evacet Cardiotoxicity Advantage Does Not Outweigh Unclear Efficacy
Executive Summary
The Liposome Company's Evacet (liposomal doxorubicin, TLC D-99) has a cardiotoxicity advantage over conventional doxorubicin when used first-line for metastatic breast cancer, the Oncologic Drugs Advisory Committee agreed Sept. 16.